你目前无法使用部分二次筛选功能
请联系客服开通更多权限和功能！
| 药品名称 | 剂型 | USP 溶出方法 | 转速（转/min） | 溶出介质 | 容积 | 推荐采样时间 | 更新时间 | 查看详情 |
|---|---|---|---|---|---|---|---|---|
| Resmetirom | Tablet | Develop a dissolution method | 2024-09-03 | 查看 | ||||
| Cenobamate | Tablet | Refer to FDA's Dissolution Guidance, 2018 | 2024-08-05 | 查看 | ||||
| Fezolinetant | Tablet | Refer to FDA's Dissolution Guidance, 2018 | 2024-08-05 | 查看 | ||||
| Leniolisib Phosphate | Tablet | I (Basket) | 100 | Acetate Buffer, pH 4.0 | 900 | 10, 20, 30, 40, 50, 60, 70 and 80 | 2024-08-05 | 查看 |
| Macitentan (MAC); Tadalafil (TAD) | Tablet | II (Paddle) | 60 | MAC: 0.05 M sodium phosphate buffer, pH 5.5 with 0.30% (w/v) CTAB; (TAD):0.05 M sodium phosphate buffer, pH 6.8 with 3.0% (w/v) polysorbate 20 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2024-08-05 | 查看 |
| Nirmatrelvir (NIR); Ritonavir (RIT) | Tablet (copackage) | II (Paddle) | 75 | NIR: 0.05 M Sodium Phosphate, pH 6.8 with 0.2% Sodium Dodecyl Sulfate; RIT: Refer to USP | 900 | 15, 20, 30, 45 and 60 | 2024-08-05 | 查看 |
| Sotagliflozin | Tablet | Develop a dissolution method | 2024-08-05 | 查看 | ||||
| Atorvastatin Calcium | Suspension | II (Paddle) | 75 | 0.05 M Phosphate Buffer, pH 6.8 | 900 | 5, 10, 15 and 30 | 2024-05-31 | 查看 |
| Baclofen | Suspension | II (Paddle) | 25 | 0.01 N HCl | 500 | 5, 10, 15, 30, 45 and 60 | 2024-05-31 | 查看 |
| Bexagliflozin | Tablet | I (Basket) | 50 | 0.1 N HCl | 900 | 1, 3, 5, 8 and 10 hours | 2024-05-31 | 查看 |
| Daprodustat | Tablet | II (Paddle) | 50 | 30 mM Phosphate Buffer, pH 6.8 | 500 for 1 mg; 900 for 2, 4, 6 and 8 mg | 5, 10, 15, 20, 25, 30, 45 and 60 | 2024-05-31 | 查看 |
| Elacestrant Dihydrochloride | Tablet | II (Paddle) | 75 | 0.01 N HCl | 500 for 100 mg; 1000 for 400 mg | 5, 10, 15, 30, 45 and 60 | 2024-05-31 | 查看 |
| Indomethacin | Suspension | Refer to USP | 2024-05-31 | 查看 | ||||
| Lacosamide | Capsule (Extended Release) | I (Basket) | 100 | Phosphate Buffer, pH 6.8 | 900 | 0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours | 2024-05-31 | 查看 |
| Omaveloxolone | Capsule | I (Basket) | 100 | 50 mM Sodium Phosphate Buffer, pH 6.8 | 900 | 10, 15, 20, 30, 45 and 60 | 2024-05-31 | 查看 |
| Oxazepam | Capsule | Refer to USP | 2024-05-31 | 查看 | ||||
| Pirtobrutinib | Tablet | II (Paddle) | 75 | Sodium Phosphate Buffer, pH 6.8 | 900 | 5, 10, 15, 20, 30, 45 and 60 | 2024-05-31 | 查看 |
| Sodium Oxybate | For Suspension (Extended Release) | II (Paddle) | 100 | Stage 1: 0.1N HCl for 2h; Stage 2: pH 6.0 Phosphate Buffer for 6h | 900 | 0.25, 1, 2, 2.5, 3, 3.5, 4 and 5 hours | 2024-05-31 | 查看 |
| Sparsentan | Tablet | II (Paddle) | 60 | 0.1 N HCl | 1000 | 5, 10, 15, 20, 30, 45 and 60 | 2024-05-31 | 查看 |
| Tasimelteon | Suspension | Refer to FDA's Dissolution Guidance, 2018 | 2024-05-31 | 查看 |
